These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 36450283)

  • 21. Loss of Neutralizing Activity of Tixagevimab/Cilgavimab (Evusheld™) Against Omicron BN.1, a Dominant Circulating Strain Following BA.5 During the Seventh Domestic Outbreak in Korea in Early 2023.
    Yang J; Hyeon S; Baek JY; Kang MS; Lee KY; Lee YH; Huh K; Cho SY; Kang CI; Chung DR; Peck KR; Won G; Lee HW; Kim K; Hwang I; Lee SY; Kim BC; Lee YK; Ko JH
    J Korean Med Sci; 2023 Jul; 38(27):e205. PubMed ID: 37431539
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld) for COVID-19 among 1112 severely immunocompromised patients.
    Nguyen Y; Flahault A; Chavarot N; Melenotte C; Cheminant M; Deschamps P; Carlier N; Lafont E; Thomas M; Flamarion E; Lebeaux D; Charlier C; Rachline A; Guérin C; Ratiney R; Touchard J; Péré H; Rozenberg F; Lanternier F; Arlet JB; Avouac J; Boussaud V; Guillemain R; Vignon M; Thervet E; Scemla A; Weiss L; Mouthon L;
    Clin Microbiol Infect; 2022 Dec; 28(12):1654.e1-1654.e4. PubMed ID: 35926762
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protection from successive Omicron variants with SARS-CoV-2 vaccine and monoclonal antibodies in kidney transplant recipients.
    Moal V; Valade M; Boschi C; Robert T; Orain N; Bancod A; Edouard S; Colson P; La Scola B
    Front Microbiol; 2023; 14():1147455. PubMed ID: 37065151
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.
    Wang XJ; Yao L; Zhang HY; Zhu KL; Zhao J; Zhan BD; Li YK; He XJ; Huang C; Wang ZY; Jiang MD; Yang P; Yang Y; Wang GL; Wang SQ; Dai EH; Gao HX; Ma MJ
    Genome Med; 2022 Dec; 14(1):146. PubMed ID: 36581867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exploratory data on the clinical efficacy of monoclonal antibodies against SARS-CoV-2 Omicron variant of concern.
    Mazzaferri F; Mirandola M; Savoldi A; De Nardo P; Morra M; Tebon M; Armellini M; De Luca G; Calandrino L; Sasset L; D'Elia D; Sozio E; Danese E; Gibellini D; Monne I; Scroccaro G; Magrini N; Cattelan A; Tascini C; ; Tacconelli E
    Elife; 2022 Nov; 11():. PubMed ID: 36413383
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different Neutralization Profiles After Primary SARS-CoV-2 Omicron BA.1 and BA.2 Infections.
    Medits I; Springer DN; Graninger M; Camp JV; Höltl E; Aberle SW; Traugott MT; Hoepler W; Deutsch J; Lammel O; Borsodi C; Puchhammer-Stöckl E; Zoufaly A; Weseslindtner L; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():946318. PubMed ID: 35928813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns.
    Gruell H; Vanshylla K; Korenkov M; Tober-Lau P; Zehner M; Münn F; Janicki H; Augustin M; Schommers P; Sander LE; Kurth F; Kreer C; Klein F
    Cell Host Microbe; 2022 Sep; 30(9):1231-1241.e6. PubMed ID: 35921836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of the replication and neutralization of different SARS-CoV-2 Omicron subvariants in vitro.
    Zhang Y; Lv Q; Qi F; Li F; Deng R; Liang X; Liu M; Yan Y; Bao L
    Animal Model Exp Med; 2023 Feb; 6(1):51-56. PubMed ID: 36808904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.
    da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D
    Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and Virological Outcome of Monoclonal Antibody Therapies Across SARS-CoV-2 Variants in 245 Immunocompromised Patients: A Multicenter Prospective Cohort Study.
    Huygens S; GeurtsvanKessel C; Gharbharan A; Bogers S; Worp N; Boter M; Bax HI; Kampschreur LM; Hassing RJ; Fiets RB; Levenga H; Afonso PM; Koopmans M; Rijnders BJA; Oude Munnink BB
    Clin Infect Dis; 2024 Jun; 78(6):1514-1521. PubMed ID: 38445721
    [TBL] [Abstract][Full Text] [Related]  

  • 31. SARS-CoV-2 Omicron sublineages show comparable cell entry but differential neutralization by therapeutic antibodies.
    Arora P; Zhang L; Krüger N; Rocha C; Sidarovich A; Schulz S; Kempf A; Graichen L; Moldenhauer AS; Cossmann A; Dopfer-Jablonka A; Behrens GMN; Jäck HM; Pöhlmann S; Hoffmann M
    Cell Host Microbe; 2022 Aug; 30(8):1103-1111.e6. PubMed ID: 35588741
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characteristics and outcomes of COVID-19 patients presumed to be treated with sotrovimab in NHS hospitals in England.
    Patel V; Levick B; Boult S; Gibbons DC; Drysdale M; Lloyd EJ; Singh M; Birch HJ
    BMC Infect Dis; 2024 Apr; 24(1):428. PubMed ID: 38649824
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cilgavimab/Tixagevimab as alternative therapeutic approach for BA.2 infections.
    Dichtl S; Zaderer V; Kozubowski V; Abd El Halim H; Lafon E; Lanser L; Weiss G; Lass-Flörl C; Wilflingseder D; Posch W
    Front Med (Lausanne); 2022; 9():1005589. PubMed ID: 36250084
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant.
    Richardson SI; Kgagudi P; Manamela NP; Kaldine H; Venter EM; Pillay T; Lambson BE; van der Mescht MA; Hermanus T; Balla SR; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; du Pisanie M; Burgers WA; Ntusi NAB; Abdullah F; Ueckermann V; Rossouw TM; Boswell MT; Moore PL
    Cell Rep Med; 2023 Jan; 4(1):100910. PubMed ID: 36603577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern.
    Aggarwal A; Akerman A; Milogiannakis V; Silva MR; Walker G; Stella AO; Kindinger A; Angelovich T; Waring E; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Jean T; Foster CSP; Christ D; Hoppe AC; Munier ML; Darley D; Churchill M; Stark DJ; Matthews G; Rawlinson WD; Kelleher AD; Turville SG
    EBioMedicine; 2022 Oct; 84():104270. PubMed ID: 36130476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2.
    Ohashi H; Hishiki T; Akazawa D; Kim KS; Woo J; Shionoya K; Tsuchimoto K; Iwanami S; Moriyama S; Kinoshita H; Yamada S; Kuroda Y; Yamamoto T; Kishida N; Watanabe S; Hasegawa H; Ebihara H; Suzuki T; Maeda K; Fukushi S; Takahashi Y; Iwami S; Watashi K
    Antiviral Res; 2022 Sep; 205():105372. PubMed ID: 35798223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants.
    Fujimoto K; Mutsuo S; Yasuda Y; Arasawa S; Tashima N; Iwashima D; Takahashi KI
    Infect Dis Rep; 2022 Dec; 14(6):996-1003. PubMed ID: 36547245
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages.
    Ai J; Wang X; He X; Zhao X; Zhang Y; Jiang Y; Li M; Cui Y; Chen Y; Qiao R; Li L; Yang L; Li Y; Hu Z; Zhang W; Wang P
    Cell Host Microbe; 2022 Aug; 30(8):1077-1083.e4. PubMed ID: 35594867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impaired neutralizing antibody efficacy of tixagevimab-cilgavimab 150+150 mg as pre-exposure prophylaxis against Omicron BA.5. A real-world experience in booster vaccinated immunocompromised patients.
    Schiaroli E; Gidari A; Brachelente G; Bicchieraro G; Spaccapelo R; Bastianelli S; Pierucci S; Busti C; Pallotto C; Malincarne L; Camilloni B; Falcinelli F; De Socio GV; Villa A; Mencacci A; Francisci D
    J Clin Virol; 2023 Nov; 168():105584. PubMed ID: 37778220
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined Antibodies Evusheld against the SARS-CoV-2 Omicron Variants BA.1.1 and BA.5: Immune Escape Mechanism from Molecular Simulation.
    Zhang J; Cong Y; Duan L; Zhang JZH
    J Chem Inf Model; 2023 Aug; 63(16):5297-5308. PubMed ID: 37586058
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.